Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: A pilot study

Urology

Volumn 65, Issue 3, 2005, Pages 543-548

  Urakami, Shinji ^a,b   Yoshino, Tateki ^a   Kikuno, Nobuyuki ^a   Imai, Shin ^a   Honda, Satoshi ^a   Yoneda, Tatuaki ^a   Kishi, Hirofumi ^a   Shigeno, Kazushi ^a   Shiina, Hiroaki ^a   Igawa, Mikio ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG FATALITY; DRUG HYPERSENSITIVITY; DYSPNEA; EDEMA; EMBOLISM; ERYTHROCYTE TRANSFUSION; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; LEUKOPENIA; LUNG INFILTRATE; MALAISE; MALE; METABOLIC DISORDER; MYELODYSPLASTIC SYNDROME; NAIL DISEASE; NAUSEA; NEUROTOXICITY; OSTEOMYELODYSPLASTIC SYNDROME; PILOT STUDY; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 20144364757     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.10.033     Document Type: Article

References (21)

1. D.P. Petrylak Chemotherapy for androgen-independent prostate cancer Semin Urol Oncol 20 2002 31 35
2. S. Urakami, M. Igawa, N. Kikuno Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer J Urol 168 2002 2444 2450
3. W.K. Kelly, T. Curley, S. Slovin Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer J Clin Oncol 19 2001 44 53
4. Y. Fromes, P. Gounon, R. Veitia Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel J Protein Chem 15 1996 377 388
5. J.F. Diaz, J.M. Andreu Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere reversibility, ligand stoichiometry, and competition Biochemistry 32 1993 2747 2755
6. A.R. Hanauske, D. Degen, S.G. Hilsenbeck Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells Anticancer Drugs 3 1992 121 124
7. S. Haldar, A. Basu, C.M. Croce Bcl2 is the guardian of microtubule integrity Cancer Res 57 1997 229 233
8. J. Verweij, M. Clavel, B. Chevalier Paclitaxel (Taxol) and docetaxel (Taxotere) not simply two of a kind Ann Oncol 5 1994 495 505
9. V. Valero, S.E. Jones, D.D. Von Hoff A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J Clin Oncol 16 1998 3362 3368
10. C.F. Verschraegen, T. Sittisomwong, A.P. Kudelka Docetaxel for patients with paclitaxel-resistant müllerian carcinoma J Clin Oncol 18 2000 2733 2739
11. D.P. Petrylak, C. Tangen, M. Hussain SWOG 99-16 randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA) (abstract) Presented at the 2004 ASCO Annual Meeting, Genitourinary Cancer, Prostate Cancer 2004
12. M.A. Eisenberger, R. De Wit, W. Berry A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC) (abstract) Presented at the 2004 ASCO Annual Meeting, Genitourinary Cancer, Prostate Cancer 2004
13. G. Gravis, F. Bladou, N. Salem Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma Cancer 98 2003 1627 1634
14. P. Therasse, S.G. Arbuck, E.A. Eisenhauer European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
15. G.J. Bubley, M. Carducci, W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467
16. W. Berry, S. Dakhil, M.A. Gregurich Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate Semin Oncol 28 2001 8 15
17. W.K. Oh, S. Halabi, W.K. Kelly A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma Cancer and Leukemia Group B 99813 Cancer 98 2003 2592 2598
18. M. Markman, K. Zanotti, K. Webster Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum Gynecol Oncol 91 2003 573 576
19. P.G. Rose, J.A. Blessing, H.G. Ball A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma a Gynecologic Oncology Group study Gynecol Oncol 88 2003 130 135
20. T.M. Beer, M. Garzotto, W.D. Henner Intermittent chemotherapy in metastatic androgen-independent prostate cancer Br J Cancer 89 2003 968 970
21. M.H. Tay, D.J. George, T.D. Gilligan Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy (abstract) Presented at the 2004 ASCO Annual Meeting, Genitourinary Cancer, Prostate Cancer 2004